Order Revofil® Fine for Clinics

Revofil® Fine is a peptide-enhanced hyaluronic acid dermal filler used by licensed clinics for refined correction of superficial facial lines. Each unit contains a prefilled 1 mL syringe with 23 mg/mL cross-linked hyaluronic acid for controlled intradermal placement in delicate treatment areas. Med spas, aesthetic practices, and healthcare professionals can order Revofil Fine for professional workflows that require subtle smoothing rather than deep structural augmentation.

This preparation is intended for experienced injectors working in the superficial dermal plane. It fits conservative treatment plans for fine static rhytids, micro-creases, and delicate etched lines in high-mobility facial zones. Clinic teams can use the product name, batch, expiry, and SKU 89592 during intake, stock rotation, and reordering.

Revofil Fine 1 mL Ordering and Clinic Price Context

Approved professional accounts can buy Revofil Fine for clinic inventory and view current contract terms after account sign-in. Pricing may vary by volume, account status, and purchasing program, so purchasing teams should use the current clinic terms displayed during ordering rather than relying on older price references. For multisite practices or planned treatment events, confirm quantities before scheduling procedures that depend on a specific lot or filler type.

Revofil Fine wholesale ordering is designed for licensed clinics and healthcare professionals. Order details, professional documentation, and facility information may be reviewed before release. This helps keep procurement aligned with professional-use products, intake records, and the clinic’s internal purchasing controls.

The product is supplied as a 1 mL prefilled syringe. It is not positioned as a volumizing filler for deep projection; it is a fine-line product for shallow dermal refinement. If your team stocks several Revofil preparations, keep Revofil Fine separated from higher-support products during receiving and treatment-room setup to reduce selection errors.

What Revofil Fine Is and How It Works

Revofil Fine dermal filler is a cross-linked hyaluronic acid gel enhanced with biomimetic peptides. Hyaluronic acid is a water-binding molecule widely used in soft-tissue filler formulations because it can support hydration and volume within the injected plane. In this product, the HA gel matrix is designed for smooth, low-volume delivery in superficial areas.

The formulation emphasizes soft integration and controlled spread rather than pronounced lift. This matters when treating thin or mobile facial tissue, where overcorrection can be more visible. Revofil Fine hyaluronic acid filler is commonly selected for careful, incremental work that preserves natural facial movement.

Clinics comparing the wider brand line can use the Revofil brand category to keep related products organized. For a deeper discussion of the brand’s HA and peptide concept, the article on Revofil filler ingredients may support staff education and formulary review.

Professional Use for Superficial Facial Lines

Revofil Fine is used for refined correction of superficial wrinkles and light facial lines. Common professional-use areas include periorbital lines, perioral lines, crow’s feet, perinasal creases, and shallow forehead marks that do not require deeper structural support. It may also fit maintenance visits after broader facial harmonization, provided the injector selects the product according to tissue quality, treatment goal, and technique.

Fine dermal filler is not a substitute for every wrinkle treatment. Dynamic expression lines may require a different plan, and deeper folds often need a product with different support characteristics. Clinics frequently coordinate superficial HA filler with neuromodulators, skin-quality procedures, or resurfacing programs according to their protocols and professional assessment.

Quick tip: Keep indication notes, injection plane, and product lot information together in the treatment record for easier follow-up and inventory reconciliation.

For clinical background on superficial-line planning, see the practice-focused discussion of fine lines and aesthetic treatment planning. For broader HA context, the article on hyaluronic acid in aesthetic medicine may help new staff understand why HA fillers are used across different tissue planes.

Key Features for Treatment-Room Workflow

• 1 mL prefilled syringe supports controlled unit-of-use setup.
• 23 mg/mL cross-linked hyaluronic acid concentration.
• Peptide-enhanced HA gel designed for superficial dermal refinement.
• Smooth extrusion profile suited to careful low-volume passes.
• Light correction role for fine lines and shallow creases.
• Batch and expiry labeling support traceability during receiving.
• SKU 89592 can help purchasing teams standardize reordering.

The practical advantage of a fine-line filler is precision. A product with lighter support can be useful when the goal is subtle texture smoothing in thin tissue, not large-volume contour change. That distinction helps clinics match product selection to the treatment area and avoid using a deeper-plane filler where a softer finish is required.

Composition, Packaging, and Handling

Revofil Fine contains cross-linked hyaluronic acid at 23 mg/mL with biomimetic peptides incorporated into the gel system. It is supplied as a 1 mL prefilled syringe for single-patient use. Excipients and full handling instructions should be confirmed against the manufacturer’s package insert and the product received by the clinic.

On receipt, staff should inspect outer packaging, seal integrity, product name, batch number, and expiry date before placing the item into stock. Maintain original packaging until point of care to preserve identification and traceability. Store the product according to the manufacturer’s labeling and your facility’s medical-product handling policy.

When logistics planning is needed, temperature-controlled handling when required and tracked US delivery can help purchasing staff align replenishment with scheduled treatment days. Do not open or stage syringes until the clinic’s procedure protocol calls for setup, and discard any product according to professional-use and facility requirements.

Safety, Contraindications, and Patient Selection

Dermal filler safety depends on product selection, injection technique, anatomy knowledge, aseptic handling, and patient screening. Expected post-injection responses can include temporary redness, swelling, bruising, tenderness, firmness, itching, or localized discomfort. Clinics should counsel patients according to their professional protocol and provide clear instructions for signs that require urgent contact.

Serious adverse events are uncommon but can occur with injectable fillers, including vascular compromise, tissue injury, infection, hypersensitivity reactions, nodules, granulomas, or visual symptoms if filler enters or compresses blood vessels. Injectors should be trained to recognize vascular warning signs and manage complications according to current professional standards. Treatment should not proceed when contraindications, active infection at the treatment site, or unsuitable tissue conditions are present.

Patient history should address prior filler reactions, allergies, immune conditions, bleeding risk, recent procedures, active skin disease, and medications or supplements that may increase bruising. Product choice and injection technique remain clinical decisions. For general education that can help correct common misconceptions during consultation, see dermal filler myths and misconceptions.

How It Fits Within a Revofil Portfolio

Revofil Fine is the lighter refinement option within a broader filler approach. Clinics may use it when the main objective is soft correction of fine superficial lines. If the treatment goal involves more visible volume support or deeper folds, another preparation in the brand family may be more appropriate.

Revofil Plus may be considered when the clinical plan requires a different support profile than a fine-line filler. Revofil Ultra may fit deeper correction strategies when the injector determines that a stronger volumizing role is needed. Selection should be based on tissue depth, mobility, desired correction, and injector familiarity with the product’s handling.

For skin-quality protocols, clinics may also review Revofil Aquashine products. Revofil Aquashine Soft Filler and Revofil Aquashine BR Soft Filler can be evaluated as adjacent options where the clinic’s treatment menu includes skin hydration or texture-focused services. These products should not be treated as automatic substitutes for Revofil Fine without confirming technique and intended use.

Clinic Procurement and Inventory Planning

Revofil Fine cost planning should account for procedure volume, expected touch-up demand, shelf-life management, and injector preference. Because aesthetic filler selection often varies by treatment zone, clinics should avoid overstocking one role while understocking adjacent products needed for harmonized plans. Forecasting based on the prior quarter’s superficial-line treatments can help purchasing teams set reorder points.

During receiving, record product name, lot, expiry, quantity, and storage placement. During use, link the syringe to the patient record according to clinic policy. This supports traceability if the manufacturer issues a notice, if an adverse event investigation is needed, or if the purchasing team audits stock movement.

For team education and product-positioning discussions, the comparison article Revofil and Juvederm selection considerations may help staff think through filler selection without replacing injector judgment. Keep internal protocols consistent so front-desk, purchasing, and clinical staff use the same product names when scheduling and stocking.

Comparable and Adjacent Products

Clinics considering alternatives should compare products by intended injection plane, rheology, package configuration, tissue response, and injector technique. A superficially placed HA filler for fine wrinkles is not interchangeable with every HA filler simply because the active material is hyaluronic acid. Differences in gel structure can affect extrusion, integration, support, and preferred placement.

Within the same brand ecosystem, Revofil Fine can sit alongside Revofil Plus, Revofil Ultra, and Aquashine preparations. This allows clinics to build protocols around fine-line correction, volume support, and skin-quality services while keeping brand familiarity for staff. If a substitution is necessary because of timing or allocation, confirm the substitute’s intended role before scheduling treatment.

Selection should remain clinician-led. Consider the patient’s anatomy, previous filler history, line depth, tissue thickness, mobility, and tolerance for conservative versus more visible correction. Document the reason for product selection when the case requires deviation from the clinic’s usual filler pathway.

Authoritative and Professional Education Notes

Hyaluronic acid fillers are medical aesthetic products that require professional judgment, sterile technique, anatomical knowledge, and appropriate adverse-event planning. Manufacturer labeling and package inserts should be the primary source for product-specific handling, contraindications, precautions, and included components. Clinic protocols should also reflect applicable professional standards and training requirements.

Use educational materials as background support, not as a replacement for product labeling or hands-on injector training. Before adding Revofil Fine to a treatment menu, confirm how it will be positioned relative to existing fillers, which staff may administer it, how complications will be escalated, and how lot records will be maintained.

Sign in to source Revofil Fine for your licensed practice and align the 1 mL HA filler with your current superficial-line protocols.

This content is for informational purposes only and is not a substitute for professional medical advice.